1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
IR Biosciences Holdings Inc.

IR Biosciences Holdings Inc.

IRBS
IR Biosciences Holdings Inc.US flagOther OTC
0.00
USD
- -
- -
128,122.00Market Cap
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
1.68
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-19.91
-16.56
-1.36
-0.87
-1.58
-0.68
-0.2
-0.48
-0.49
-0.49
- -
-0.35
Free Cash Flow per Basic Share
-20.59
-8.97
-1.1
-0.47
-0.31
-0.28
-0.28
-0.22
-0.41
-0.22
- -
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-19.81
-34.59
-25.43
-0.89
-2.13
-1.73
-1.8
-1.63
-2.08
-2.1
- -
-2.15
Tangible Book Value per Share
10.13
-5.57
-4.4
-0.4
0.18
-0.33
0.32
-0.05
-0.36
-0.68
- -
-0.87
Basic Weighted Avg Shares
- -
- -
- -
2
3
7
7
11
12
13
- -
15
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-1,211.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
- -
-2
-5
-5
-1
-5
-6
-6
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,184.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-1
-1
-1
1
-2
2
-1
1
-3
-6
-6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
5
4
- -
- -
Total Equity
1
-1
-1
-1
1
-2
2
-1
-4
-9
-13
-13
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.93
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
ST Debt
3
- -
4
LT Borrowings
4
3
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
17
17
Market Capitalization
2
1
1

Working Capital

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
2
7
Payables & Accruals
2
2
3
ST Debt
3
- -
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-31.26%
92.45%
47.55%
Free Cash Flow
40.46%
-0.44%
-85.05%
Net Income, GAAP
100.96%
39.86%
-18.33%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.11
-0.08
-0.17
- -
-0.49
2009
-0.16
-0.15
-0.23
- -
-0.49
2010
-0.24
0.08
-0.18
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Chet Leach D.A.B.T.
Full Time Employees
4
Sector
Healthcare
Industry
Biotechnology
Address
8777 East Via de Ventura Scottsdale United States of America
IPO Date
Jun 27, 2023
Similar Companies
ChitogenX Inc. (CHNXF)
IMV Inc. (IMVIQ)
Arrowhead Pharmaceuticals, Inc. (0HI3.L)
RenovoRx, Inc. (RNXT)
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
ImmuCell Corporation (ICCC)
Business
IR BioSciences Holdings Inc. is a development-stage biotechnology company focused on the research and development of immunomodulatory therapies derived from modified Substance P. Through its wholly owned subsidiary ImmuneRegen BioSciences Inc., the company develops drug candidates including Homspera, Radilex, and Viprovex for applications in pulmonology, immunology, and hematology; these target pulmonary fibrosis, influenza infection, radiation-induced neutropenia, vaccine adjuvant activity against certain cancers, wound healing, and immune system regeneration via adult stem cell stimulation. Founded in 1999 and headquartered in Scottsdale, Arizona, the company operates primarily in the United States with a small team of four employees and maintains its focus on preclinical and early-stage research without recent commercialized products. No major recent partnerships, acquisitions, funding rounds, product launches, or strategic shifts have been reported in the last one to two years, reflecting its ongoing development-stage status amid limited public updates.